Want to know what's happening next in healthcare?

MedCityNews is the leading online news source for the business of innovation in healthcare.


“I read MedCity because it captures the pulse of what's going on in healthcare innovation, a go to source. I also like how MedCity supports women in digital health.”

Dr. Charlene Ngamwajasat, @doctorcharlene, Physician and techie


Sign up for our daily newsletter


Minnesota hypertension treatment firm names new chief commercial officer

1:21 pm by | 0 Comments

Privately held CVRx that has created an implantable device to treat high blood pressure announced Monday that it has named  Philippe Wanstok to the newly created position of chief commercial officer.

Wanstok will oversee the worldwide commercialization of the neurostimulation product called the Barostim Neo, which bear the CE Mark and is currently available in  Germany, Italy, The Netherlands, Switzerland and Austria. While the device received European approval in August 2011, it has run into some difficulties in the U.S.

Previously Wanstok was International General Manager of Commercial Operations with the Cardiac Rhythm Disease Management division at Medtronic. He led  a worldwide team of 3,000 and the business generated more than $2.4 billion of revenues in active implantable devices.

“We are thrilled to have Philippe join the CVRx team,” said Nadim Yared, President and CEO of CVRx, in a news release. “Philippe’s consistently superb track record of accomplishments in the active implantable medical device market makes him ideally suited to lead CVRx’s worldwide commercial activities.”

Advertisement

An improvement upon the original Rheos system, the Barostim neo provides electrical stimulation to activate the baroreceptors – the blood pressure sensors responsible for cardiovascular function.

However, in the U.S. the company has found it difficult to get its device approved.

“We had a trial in the U.S. but it didn’t meet the clinical endpoint,” said John Brintnall, CVRx’s CFO in a phone interview. “We are in discussions with the FDA to design a new one and hope to have that started some time in 2012.”

 

Copyright 2014 MedCity News. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Arundhati Parmar

By Arundhati Parmar

Arundhati Parmar is the Medical Devices Reporter at MedCity News. She has covered medical technology since 2008 and specialized in business journalism since 2001. Parmar has three degrees from three continents - a Bachelor of Arts in English from Jadavpur University, Kolkata, India; a Masters in English Literature from the University of Sydney, Australia and a Masters in Journalism from Northwestern University in Chicago. She has sworn never to enter a classroom again.
More posts by Author

0 comments

Hear the latest news first

Get our daily newsletter or follow us.

 

Advertisement